P. LoRusso

614 total citations
21 papers, 510 citations indexed

About

P. LoRusso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, P. LoRusso has authored 21 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in P. LoRusso's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). P. LoRusso is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). P. LoRusso collaborates with scholars based in United States, Belgium and United Kingdom. P. LoRusso's co-authors include Keith D. Wilner, M. Naveed Shaik, Mark A. Dickson, Ronan Courtney, Peter J. O’Dwyer, Sophia Randolph, Gary K. Schwartz, Geoffrey I. Shapiro, Scott A. Boerner and J. W. Clark and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

P. LoRusso

21 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. LoRusso United States	9	340	311	201	80	73	21	510
Patricia Tresca France	13	350 1.0×	190 0.6×	141 0.7×	127 1.6×	63 0.9×	26	542
Hidenori Mizugaki Japan	14	400 1.2×	231 0.7×	207 1.0×	92 1.1×	38 0.5×	40	710
Lucia Trandafir Switzerland	11	247 0.7×	272 0.9×	280 1.4×	85 1.1×	73 1.0×	22	634
Amy Freyman United States	7	418 1.2×	326 1.0×	263 1.3×	34 0.4×	52 0.7×	12	657
Amy Tilley United States	5	309 0.9×	207 0.7×	106 0.5×	96 1.2×	39 0.5×	5	444
L. Véronèse Switzerland	10	428 1.3×	280 0.9×	388 1.9×	71 0.9×	85 1.2×	17	664
Vivian Ng United States	7	709 2.1×	404 1.3×	205 1.0×	88 1.1×	52 0.7×	10	955
Bernhard Heinrich Germany	14	439 1.3×	187 0.6×	160 0.8×	66 0.8×	52 0.7×	36	630
Dénes Csonka Switzerland	5	148 0.4×	191 0.6×	231 1.1×	70 0.9×	57 0.8×	14	464
Douglas Robinson United States	8	236 0.7×	196 0.6×	255 1.3×	110 1.4×	59 0.8×	15	481

Countries citing papers authored by P. LoRusso

Since Specialization

Citations

This map shows the geographic impact of P. LoRusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. LoRusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. LoRusso more than expected).

Fields of papers citing papers by P. LoRusso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. LoRusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. LoRusso. The network helps show where P. LoRusso may publish in the future.

Co-authorship network of co-authors of P. LoRusso

This figure shows the co-authorship network connecting the top 25 collaborators of P. LoRusso. A scholar is included among the top collaborators of P. LoRusso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. LoRusso. P. LoRusso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Champiat, Stéphane, Martin Wermke, Cécile Vicier, et al.. (2022). 732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial. Annals of Oncology. 33. S877–S878. 1 indexed citations

Chung, Hyun Cheol, Kyungwon Lee, Justin F. Gainor, et al.. (2021). SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals of Oncology. 32. S215–S216. 10 indexed citations

Puzanov, Igor, Karin Havenith, Joseph Boni, et al.. (2020). 1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation. Annals of Oncology. 31. S710–S711. 1 indexed citations

Hamilton, E.P., Neelima Vidula, P. LoRusso, et al.. (2019). Abstract OT1-02-02: A phase 1, first-in-human, multi-part study of RAD140, an oral nonsteroidal selective androgen receptor modulator, in postmenopausal women with hormone receptor positive breast cancer. Cancer Research. 79(4_Supplement). OT1–2. 1 indexed citations

Hamilton, Erika, Neelima Vidula, X. Cynthia, et al.. (2019). Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC). Annals of Oncology. 30. v123–v123. 3 indexed citations

Hendriks, Bart S., Anthony F. Shields, Barry A. Siegel, et al.. (2014). PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients. Annals of Oncology. 25. i19–i19. 10 indexed citations

LoRusso, P., et al.. (2014). 210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers. European Journal of Cancer. 50. 71–71. 1 indexed citations

Shapiro, Geoffrey I., Mark R. Middleton, Howard A. Burris, et al.. (2013). Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12. 3 indexed citations

Hunsberger, Sally, et al.. (2012). Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials. JNCI Journal of the National Cancer Institute. 104(24). 1860–1866. 30 indexed citations

10.

Schwartz, Gary K., P. LoRusso, Mark A. Dickson, et al.. (2011). Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). British Journal of Cancer. 104(12). 1862–1868. 221 indexed citations

11.

LoRusso, P., et al.. (2011). Pharmacokinetic and pathophysiologic covariates influencing treatment outcomes with T-DM1 in patients with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 633–633. 1 indexed citations

12.

Shapiro, Geoffrey I., P. LoRusso, Luna Musib, et al.. (2011). Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3005–3005. 40 indexed citations

13.

Camidge, D. Ross, Yung‐Jue Bang, E.L. Kwak, et al.. (2011). Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 2501–2501. 102 indexed citations

14.

Sosman, J. A., Alex A. Adjei, P. LoRusso, et al.. (2011). First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.. Journal of Clinical Oncology. 29(15_suppl). TPS145–TPS145. 3 indexed citations

15.

Braña, Irene, P. LoRusso, José Baselga, et al.. (2010). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 28(15_suppl). 3030–3030. 45 indexed citations

16.

Gupta, SK, et al.. (2010). 363 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit. European Journal of Cancer Supplements. 8(7). 115–115. 1 indexed citations

17.

LoRusso, P., Andy Ryan, & Scott A. Boerner. (2008). Small-Molecule Tyrosine Kinase Inhibitors. 457–468. 8 indexed citations

18.

Slapak, Christopher A., P. LoRusso, Dinesh P. de Alwis, et al.. (2007). Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2542–2542. 3 indexed citations

19.

Albanell, Joan, Federico Rojo, Steven D. Averbuch, et al.. (2001). Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition. European Journal of Cancer. 37. S159–S159. 1 indexed citations

20.

Foster, Brenda J., Lynne A. Jones, Richard Wiegand, P. LoRusso, & Thomas H. Corbett. (1997). Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline). Investigational New Drugs. 15(3). 187–194. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact